Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rezende Izabela Maurício, Pereira Leonardo Soares, Fradico Jordana Rodrigues Barbosa, Pascoal Xavier Marcelo Antônio, Alves Pedro Augusto, Campi-Azevedo Ana Carolina, Speziali Elaine, Dos Santos Lívia Zignago Moreira, Albuquerque Natalia Soares, Penido Indiara, Santos Tayrine Araujo, Bom Ana Paula Dinis Ano, da Silva Andrea Marques Vieira, Fernandes Camilla Bayma, Calzavara Carlos Eduardo, Kroon Erna Geessien, Martins-Filho Olindo Assis, Teixeira-Carvalho Andréa, Drumond Betânia Paiva
Аннотация
One patient presented hyporexia, asthenia, adynamia, and jaundice two months after acute yellow fever (YF) onset; plus laboratory tests indicating hepatic cytolysis and a rebound of alanine and aspartate transaminases, and total and direct bilirubin levels. Laboratory tests discarded autoimmune hepatitis, inflammatory or metabolic liver disease, and new infections caused by hepatotropic agents. Anti-YFV IgM, IgG and neutralizing antibodies were detected in different times, but no viremia. A liver biopsy was collected three months after YF onset and tested positive for YFV antigens and wild-type YFV-RNA (364 RNA-copies/gram/liver). Transaminases and bilirubin levels remained elevated for five months, and the arresting of symptoms persisted for six months after the acute YF onset. Several serum chemokines, cytokines, and growth factors were measured. A similar immune response profile was observed in the earlier phases of the disease, followed by more pronounced changes in the later stages, when transaminases levels returned to normal. The results indicated viral persistence in the liver and continual liver cell damage three months after YF onset and reinforced the need for extended follow-ups of YF patients. Further studies to investigate the role of possible viral persistence and the immune response causing relapsing hepatitis following YF are also necessary.